Acrivon Therapeutics, Inc.ACRV
Price (close)
$2.10
Market cap
$90.0M
P/E
—
Revenue (TTM)
—
Net income
-$74.2M
Dividend yield
—
1-year total return
36.4%
Net margin
—
Revenue growth
—
Debt / equity
—
What Acrivon Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | — | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Free cash flow | — | -$14.2M | -$32.3M | -$43.9M | -$68.4M | -$65.3M |
More on ACRV.
- Acrivon Therapeutics, Inc. summary
- Acrivon Therapeutics, Inc. financial statements
- Acrivon Therapeutics, Inc. key metrics
- Acrivon Therapeutics, Inc. health scores and style box
- Acrivon Therapeutics, Inc. earnings
- Acrivon Therapeutics, Inc. dividends
- Acrivon Therapeutics, Inc. valuation
- Acrivon Therapeutics, Inc. ownership and insiders
- Acrivon Therapeutics, Inc. peers
Figures from Acrivon Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.